Financial Performance - Operating revenue for the period was ¥1,301,217,382.71, representing a year-on-year growth of 35.54%[11] - Net profit attributable to shareholders was ¥47,955,112.28, a significant increase of 693.98% compared to the same period last year[12] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,492,912.12, up from a loss of ¥4,553,556.66 in the previous year[11] - Operating profit surged to ¥59,642,621.50, a remarkable increase of 332.17% driven by higher gross profit[18] - Net profit for Q1 2021 was ¥60,368,645.93, a substantial rise from ¥10,367,468.76 in Q1 2020, showcasing improved profitability[36] Assets and Liabilities - Total assets at the end of the reporting period reached ¥7,544,777,894.62, an increase of 3.72% compared to the end of the previous year[11] - Total liabilities rose to ¥4,132,484,728.42, compared to ¥3,913,554,693.04[26] - Shareholders' equity increased to ¥3,412,293,166.20, up from ¥3,359,270,143.02[26] - Total assets increased to ¥7,544,777,894.62, up from ¥7,272,824,836.06[24] - Total operating costs for Q1 2021 were ¥1,242,225,586.28, up from ¥954,981,063.65 in Q1 2020, reflecting a significant increase in operational expenses[36] Cash Flow - Cash flow from operating activities showed a net outflow of ¥21,023,245.89, an improvement from a net outflow of ¥79,185,003.48 in the previous year[11] - Cash inflow from operating activities totaled 582,593,742.02 RMB, up from 439,399,934.75 RMB year-over-year, reflecting a 32.5% increase[50] - The net cash flow from operating activities was -69,108,494.01 RMB, an improvement from -86,456,336.00 RMB in the previous year, indicating a reduction in cash outflow[50] - Cash outflow for operating activities was 651,702,236.03 RMB, compared to 525,856,270.75 RMB in the prior year, representing a 23.9% increase[50] Expenses - Sales expenses reached ¥162,764,591.00, a 51.06% increase driven by higher marketing costs[18] - R&D expenses amounted to ¥55,239,151.06, up 55.07% due to increased investment in research[18] - R&D expenses increased to ¥55,239,151.06 in Q1 2021, compared to ¥35,621,421.06 in Q1 2020, indicating a focus on innovation[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 151,747[14] Other Financial Metrics - The weighted average return on net assets increased by 1.22 percentage points to 1.42%[11] - Basic and diluted earnings per share for Q1 2021 were both ¥0.05, compared to ¥0.01 in Q1 2020[43] - The total comprehensive income for Q1 2021 was approximately ¥48.60 million, significantly higher than ¥7.49 million in Q1 2020[39] - The tax expenses for Q1 2021 were approximately ¥10.77 million, compared to ¥2.88 million in Q1 2020, indicating an increase in tax burden[39]
鲁抗医药(600789) - 2021 Q1 - 季度财报